Construction method of transgenic mouse model for expressing plant gene OsTir1
By constructing an OsTir1 expression cassette with the Loxp-Stop-Loxp sequence in the mouse genome using CRISPR/Cas9 and In-Fusion technologies, the embryonic lethality problem of OsTir1 in mouse models was solved, and efficient expression of OsTir1 protein in mice was achieved, thus constructing a rapid and complete protein degradation system model.
Patent Information
- Application Number
- CN202411043530.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-31
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies make it difficult to construct mouse models that stably express OsTir1, which limits the application of protein degradation systems in mammals. Furthermore, the non-specific protein degradation caused by traditional knockout methods affects embryonic development and has a low success rate.
The OsTir1 expression cassette, a plant gene, with the Loxp-Stop-Loxp sequence was knocked into the mouse genome using CRISPR/Cas9 technology. A transgenic mouse model expressing OsTir1 was constructed using homologous recombination repair and In-Fusion technology. The Kozak and rBG pA sequences were used to improve translation initiation and transcription termination efficiency, and resistance gene sequences were introduced for screening.
A transgenic mouse model expressing OsTir1 was successfully constructed, achieving efficient expression of OsTir1 protein in mice, solving the embryo lethality problem, and providing a rapid, complete, and reversible protein degradation system model.
Smart Images

Figure BDA0004972940420000061 
Figure BDA0004972940420000071 
Figure BDA0004972940420000081
Abstract
Description
Technical Field
[0001] The present invention relates to the construction of an animal model of a protein rapid degradation system, and specifically to the construction of a donor plasmid containing a plant gene OsTir1 cDNA containing a point mutation as a target gene sequence, 6*SV40 polyA as a core transcription termination sequence, and a sequence promoting the expression of the target gene by using the In-Fusion technology, and then using the plasmid to construct a transgenic mouse model expressing OsTir1. Background Art
[0002] AID (Auxin-inducible degron) is a protein degradation pathway evolved by plants. It uses plant growth hormones, such as indole-3-acetic acid (IAA), to act on the SCF complex in plant cells, inducing ubiquitination of inhibitors of the AUX / IAA protein family, thereby activating the expression of AUX / IAA family proteins and promoting plant growth and development (Blázquez et al., 2020, Tan et al., 2007). The SCF complex is a member of the E3 ubiquitin ligase family, which contains three key subunits (Skp1, Cul1 and F-box). The Cul1 subunit acts as the main scaffold, bringing Skp1 and Rbx1 together. Rbx1 is responsible for recruiting E2 ubiquitin conjugating enzymes to the complex; while Skp1 binds to the F-box protein, which interacts with substrates containing degradation motifs to degrade proteins (Tan, et al., 2007). Transport inhibitor response 1 (TIR1) is a plant-specific F-box protein. In plants, growth hormone first binds to TIR1 and is recognized by AUX / IAA. SCF-TIR1 then recruits E2 ubiquitin conjugating enzymes to degrade AUX / IAA protein family transcriptional repressors through ubiquitination (Dharmasiri et al., 2005, Kepinski and Leyser, 2005). The SCF complex is highly conserved in eukaryotes (Skaar et al., 2013). Although other eukaryotes do not have a direct response to plant growth hormones, they have SCF-mediated protein degradation pathways, which suggests that it is possible to apply the plant growth hormone-induced protein degradation system to other eukaryotic organisms.
[0003] Nishimura et al. first applied AID in eukaryotic cell lines such as yeast, chicken, mouse, hamster and human. They fused an AID sequence (derived from the AUX / IAA sequence and recognized by TIR1) to the N-terminus or C-terminus of the target gene, expressed exogenous Arabidopsis TIR1, and then induced the degradation of the target protein by plant growth hormone (Nishimura et al., 2009). Since Arabidopsis TIR1 denatures when incubated at the temperature required for animal cell culture, Nishimura et al. used the rice ortholog OsTIR1 (specifically its mutant OsTIR1 (F74G)) which is more stable at high temperatures. After growth hormone treatment, the target protein is degraded very quickly (half-life is 10 to 20 minutes), and the target protein expression can be restored by removing growth hormone (Nishimura, et al., 2009). The emergence of CRISPR-Cas9 technology has made it easier to construct the AID system. For example, an AID (mAID) of only 7 kD can be knocked into the C-terminus of the target gene in mammalian cells. After expressing OsTir1, IAA is added to rapidly degrade the protein encoded by the target gene within 60 minutes (Natsume et al., 2016).
[0004] The AID system responds rapidly to growth hormone, and the degradation of target proteins is rapid, complete and reversible, and can be applied to cell lines of a wide range of species. Since traditional knockout and knockdown methods cannot accurately explore the direct regulatory mechanism of proteins, the application of the AID system in mammals is of great significance for researchers to explore processes that occur in a very short time (such as mitosis, transcription initiation, etc.), proteins essential for growth and development, three-dimensional genome structure and other related research. The successful construction of model animals for the AID system is extremely important for studying the functions of some target proteins. For example, a study constructed a mouse transgenic line in which the CAG promoter at the Rosa26 site drove the expression of the plant gene OsTir1, but the results showed that the mouse embryos were lethal (Yesbolatova et al., 2020). This may be due to the transient expression of OsTir1 from many copies of the injected donor plasmid, which leads to non-specific protein degradation in the embryo, thereby affecting embryonic development.
[0005] In addition, for models constructed based on the conditional expression pattern of the flox region, the function of the related protein is usually studied indirectly by knocking out the target gene. After the knockout occurs, a Loxp sequence is usually retained in the animal genome. Since the target gene is knocked out, the effect of the Loxp sequence on the expression of the target gene in the genome is uncertain. This uncertainty may lead to a low success rate of model construction for some models constructed by homologous recombination and Loxp-Stop-Loxp sequences (for example, in the protein expression verification of animal samples, sometimes only tag expression is observed but the protein expression band is missing).
[0006] In summary, constructing OsTir1-expressing mice is particularly critical for the construction of model animals for the AID system. Summary of the invention
[0007] The purpose of the present invention is to provide a method for constructing a transgenic mouse model expressing the plant gene OsTir1, so as to lay a foundation for further constructing a protein rapid degradation system model mouse.
[0008] In order to achieve the above object, the present invention adopts the following technical solutions:
[0009] The mouse model construction method comprises the following steps:
[0010] 1) knocking in a plant gene OsTir1 expression cassette containing a Loxp-Stop-Loxp sequence into a mouse genome as a target sequence to obtain a knock-in mouse; wherein the plant gene OsTir1 expression cassette comprises a Kozak sequence, an OsTir1 coding sequence and an rBG pA sequence;
[0011] 2) The knock-in mice were used to remove the Loxp-Stop-Loxp sequence in the genome through homologous recombination to obtain mice with tissue-specific expression of the plant gene Ostir1.
[0012] Preferably, in step 1, the target sequence is knocked into the first intron of the Rosa26 gene on mouse chromosome 6 using CRISPR / Cas9 technology and homologous recombination repair.
[0013] Preferably, the homologous recombination repair is performed on the double-stranded DNA break of the Rosa26 gene caused by the Cas9 protein bound to the vicinity of the knock-in site under the guidance of gRNA, and the knock-in site is located at the gRNA target site in the first intron of the Rosa26 gene, and the sequence of the target site is as follows: 5'—CTCCAGTCTTTCTAGAAGATGGG—3'.
[0014] Preferably, the donor vector used in the homologous recombination repair comprises a 5' homology arm, a 3' homology arm, and a promoter for expressing the plant gene OsTir1, a Loxp-Stop-Loxp sequence with the transcription termination sequence 6*SV40 pA as the core, and an expression sequence with the Kozak sequence and the plant gene OsTir1 CDS sequence (or the mutated plant gene OsTir1 CDS sequence) and the rBG pA sequence as the core, which are arranged in sequence from the 5' homology arm to the 3' homology arm; wherein the 5' homology arm is a sequence fragment homologous to a 2.1-2.2 kb DNA sequence upstream of the knock-in site in the first intron of the Rosa26 gene, and the 3' homology arm is a sequence fragment homologous to a 2.1-2.2 kb DNA sequence downstream of the knock-in site in the first intron of the Rosa26 gene.
[0015] Preferably, the promoter used to express the plant gene OsTir1 is a CAG promoter.
[0016] Preferably, the Donor vector further comprises a tag sequence (eg, a V5 tag sequence) for identifying whether the plant gene OsTir1 is expressed or not.
[0017] Preferably, the Loxp-Stop-Loxp sequence specifically includes a termination transcription box located between the 5' end loxP and the 3' end loxP, and the termination transcription box includes a PGK promoter and a 6*SV40 pA sequence.
[0018] Preferably, the termination transcription box further comprises a resistance gene sequence located between the PGK promoter and the 6*SV40 pA sequence.
[0019] Preferably, the termination transcription box comprises a PGK promoter, a neomycin resistance gene sequence (Neo or NeoR) and a 6*SV40 pA sequence arranged in sequence.
[0020] Preferably, the step 1 specifically comprises the following steps:
[0021] 1.1) constructing a Donor vector using the 5' homology arm, CAG promoter, Loxp-Stop-Loxp sequence, the expression sequence and the 3' homology arm as the main body;
[0022] 1.2) gRNA, Cas9 protein and the constructed Donor vector are introduced into the fertilized eggs of wild-type mice, and then the fertilized eggs are transplanted into pseudo-pregnant female mice (the Cas9 protein binds to the target site located in the first intron of the Rosa26 gene under the guidance of gRNA, and then the Cas9 protein cuts near the PAM region of the target site it recognizes and causes double-strand breaks in the Rosa26 gene DNA, thereby initiating homologous recombination repair), and the pseudo-pregnant female mice produce F0 generation mice;
[0023] 1.3) F0 mice are mated with wild-type mice to obtain F1 mice, and heterozygous transgenic mice that retain the target sequence in the F1 mice are self-fertilized, and then homozygous transgenic mice that retain the target sequence in the offspring mice are identified to obtain homozygous transgenic mice that can be used for breeding with tissue-specific Cre tool mice, i.e., knock-in mice.
[0024] Preferably, the 5' homology arm is shown in SEQ.ID.NO.2, the CAG promoter is shown in SEQ.ID.NO.3, the Loxp-Stop-Loxp sequence is shown in SEQ.ID.NO.4, the expression sequence is shown in SEQ.ID.NO.5, and the 3' homology arm is shown in SEQ.ID.NO.6.
[0025] Preferably, step 2 specifically includes the following steps: mating the knock-in mouse with a tissue-specific Cre tool mouse to obtain Cre-positive heterozygous transgenic offspring, i.e., transgenic mice expressing the plant gene OsTir1.
[0026] Preferably, the Cre tool mouse is a Pax7-Cre tool mouse, and the Cre enzyme of the tool mouse is specifically expressed in muscle tissue.
[0027] Preferably, the mouse model construction method specifically comprises the following steps: connecting a fragment containing a 5' homology arm, a fragment containing a CAG promoter, a fragment containing a loxP-PGK-Neo-6*SV40 pA-loxP sequence, a fragment containing a Kozak-OsTI R1 (F74G)-V5 tag-rBG pA sequence, and a fragment containing a 3' homology arm to a vector backbone using In-Fusion technology, wherein OsTIR1 (F74G) is a coding sequence of a mutant OsTIR 1 in which the 74th amino acid is mutated from phenylalanine to glycine (i.e., a mutant plant gene OsTir1 CDS sequence); the ligation product is transformed, screened by single clones, and verified by bacterial liquid PCR and sequencing to obtain a Donor vector; the obtained Donor vector, gRNA, and Cas9 protein are simultaneously microinjected into fertilized eggs of wild-type mice (e.g., C57BL / 6J mice), the microinjected fertilized eggs are transplanted into pseudo-pregnant female mice (e.g., C57BL / 6J mice) and F0 generation mice are produced, and then the heterozygous mice containing the target sequence (i.e., the positive F0 generation heterozygous mice with completed knock-in) are identified by PCR and sequencing; the knock-in After the positive F0 generation heterozygous mice are mated with wild-type mice (such as C57BL / 6J mice), the obtained F1 generation mice are identified by PCR and self-pollinated. Then, the homozygous transgenic mice of the offspring (such as F2 generation) are mated with muscle-specific Pax7-Cre tool mice (such as modified from C57BL / 6J mice). Then, the Cre-positive heterozygous transgenic mice of the offspring (such as F3 generation) containing the plant gene OsTir1 expression cassette (i.e., the CAG promoter-loxP-Kozak-OsTIR1(F74G)-V5 tag-rBG pA sequence formed by mating with Cre tool mice to remove the loxP-PGK-Neo-6*SV40 pA-loxP in the target sequence contained in the transgenic mouse parent) are identified by PCR, thereby obtaining transgenic mice that specifically express the plant gene OsTir1 in muscle tissue.
[0028] The beneficial effects of the present invention are embodied in:
[0029] The present invention utilizes CRISPR / Cas9 technology to knock-in a plant gene Ostir1 expression cassette with a Loxp-Stop-Loxp sequence at a fixed point in the mouse genome, which can not only delete the sequence in the mouse offspring through the principle of homologous recombination to achieve activation of the expression cassette, thereby constructing a transgenic mouse model expressing the plant gene Ostir1, but also provides a mouse sample capable of efficiently expressing exogenous OsTIR1 protein for further construction of a protein rapid degradation system model mouse through the synergistic effect of a Kozak sequence for enhancing the initiation of mRNA translation and an rBG pA sequence for improving the efficiency of terminating transcription in the expression cassette.
[0030] Furthermore, the present invention solves the problem that only using the 6*SV40 pA sequence cannot avoid embryonic lethality in plant gene OsTir1 knock-in mice (e.g., F0 generation mice) by optimizing the target sequence with the "Loxp-Stop-Loxp sequence" as the conditional activation element, that is, introducing a transcription termination box composed of a PGK promoter and a 6*SV40 pA sequence into the Loxp-Stop-Loxp sequence.
[0031] Furthermore, the present invention introduces a resistance gene sequence (such as Neo or NeoR) into the above-mentioned transcription termination box, which not only introduces a eukaryotic selection marker into the plant gene OsTir1 knock-in mouse, but also allows the plant gene OsTir1 expression cassette (such as CAG promoter-loxP-Kozak-OsTIR1(F74G)-V5 tag-rBG pA sequence) formed by the target sequence based on CAG-Loxp-Stop-Loxp after homologous recombination to be normally expressed in mice (for example, specifically expressed in muscle tissue).
[0032] Furthermore, the present invention aims at the F0 generation positive mice (i.e., the positive F0 generation heterozygous mice with knock-in) constructed by using CRISPR / Cas9 technology, which will have different genetic lineages due to the cutting efficiency and possible non-homologous repair. The F0 generation positive mice are mated with wild-type mice to obtain F1 generation positive mice with stable genotypes. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is a schematic diagram of a transgenic mouse model expressing the plant gene Ostir1 constructed using CRISPR / Cas9 technology in an embodiment of the present invention.
[0034] Figure 2 This is a plasmid map of the Donor vector used for homologous recombination repair in the examples of the present invention.
[0035] Figure 3 This is a diagram of the PCR identification strategy for the F0 and F1 generation mouse genotypes in the examples of the present invention.
[0036] Figure 4 This is the electrophoresis diagram for PCR identification of the F0 generation mouse genotype in the embodiment of the present invention.
[0037] Figure 5 This is the sequencing diagram of the knock-in (Knockin, KI) sequence of the F0 generation mice in the example of the present invention.
[0038] Figure 6 This is the electrophoresis diagram for PCR identification of the F1 generation mouse genotype in the example of the present invention.
[0039] Figure 7 This is the electrophoresis diagram for PCR identification of the F2 generation mouse genotype in the embodiment of the present invention.
[0040] Figure 8 This is a diagram of the strategy for breeding Ostir1-expressing mice by mating F2 mice with Cre-expressing mice in an embodiment of the present invention.
[0041] Fig. 9 This is an electrophoresis diagram of PCR identification for testing Cre activity in an embodiment of the present invention.
[0042] Fig.10 This is a Western blot identification diagram for testing the expressed OsTIR1 protein in the examples of the present invention. DETAILED DESCRIPTION
[0043] The present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. The embodiments are only used to explain the present invention, but not to limit the scope of protection of the present invention.
[0044] (I) Construction of a transgenic mouse model expressing the plant gene Ostir1
[0045] 1. Targeting the plant gene Ostir1, a mouse transgenic strategy was designed, and the target sequence was knocked into the first intron of the Rosa26 gene (NCBI reference sequence: NR_027008.1) on mouse chromosome 6 using CRISPR / Cas9 technology. Figure 1 shown.
[0046] 2. gRNA was designed based on the CRISPR / Cas9 system. The sequence of the first intron-specific gRNA action site of the Rosa26 gene is shown in Table 1.
[0047] Table 1. gRNA action sites
[0048] Sequence (5'-3') Sequence Listing CTCCAGTCTTTCTAGAAGATGGG SEQ.ID.NO.1
[0049] Note: The italic bases in the sequence are PAM.
[0050] 3. The Donor vector was designed based on the principle of homologous recombination repair and in combination with the knock-in target sequence (referred to as the knock-in sequence). The Donor vector contains homology arms, a Loxp-Stop-Loxp sequence with the transcription termination sequence 6*SV40 pA as the core, and an expression sequence with Kozak, Ostir1 cDNA and rBG pA as the core. Its main components are shown in Table 2-1, and the nucleotide sequences of the corresponding elements are shown in Table 2-2.
[0051] Table 2-1. Main components of Donor carrier
[0052]
[0053] Table 2-2. Partial nucleotide sequence of Donor vector
[0054]
[0055]
[0056]
[0057]
[0058]
[0059]
[0060]
[0061] Combination Figure 1 As shown in Table 2-1 and Table 2-2, the knock-in sequence contained in the Donor vector has the following structure: CAGpromoter-loxP-PGK-Neo-6*SV40 pA-loxP-Kozak-OsTIR1(F74G)-V5 tag-rBG pA. 4. Using mouse tissue (C57BL / 6J mice, collected in April 2022) DNA as a template, primers 5'arm-F and 5'arm-R were used to amplify the fragment containing the 5' homology arm by PCR (denoted as fragment-1, in which the 5' homology arm is 2114bp); using the plasmid purchased from Addgene (Plasmid#170520) as a template, primers CAG-F and CAG-R were used to amplify the fragment containing the CAG promoter by PCR (denoted as fragment-2, in which the CAG promoter is 1726bp); using Loxp-PGK-Neo-6*SV40 pA-Loxp plasmid (synthesized by Shanghai Bioengineering Co., Ltd.) was used as a template, and primers Loxp-F and Loxp-R were used to amplify a fragment containing the Loxp-Stop-Loxp sequence by PCR (denoted as fragment-3, in which the Loxp-Stop-Loxp sequence was 3270 bp); OsTIR1(F74G)-V5 tag-rBGpA plasmid (synthesized by Shanghai Bioengineering Co., Ltd.) was used as a template, and primers OsTIR1-F and rBG pA-R were used to amplify a fragment containing the Kozak-OsTIR1(F74G)-V5 tag-rBG pA sequence by PCR (denoted as fragment-4, in which the Kozak-OsTIR1(F74G)-V5 tag-rBG pA sequence was 2316 bp); mouse tissues (C57BL / 6J mice,
[0062] The DNA was collected in April 2022 as a template and primers 3'arm-F and 3'arm-R were used to amplify the 3'
[0063] The fragment of the homology arm (denoted as fragment-5, wherein the 3' homology arm is 2153 bp) was subjected to gel electrophoresis to cut out the target band, and the DNA was recovered and purified using a DNA gel recovery kit (OMEGA, D2000).
[0064] Among them, the specific primers used for PCR amplification are shown in Table 3:
[0065] Table 3. PCR amplification primers
[0066] Primer name Sequence (5'-3') Primer Type Sequence Listing 5'arm-F GGCGAATTGGGTACGGCGCGCCACGAGCGACCAG Upstream primer SEQ.ID.NO.7 5'arm-R AATAATCAATGAAAGACTGGAGTGTGCAGATCACGAGGGAAG Downstream primer SEQ.ID.NO.8 CAG-F AACTCCAGTCTTTCATTGATTATTGACTAGTTATTAATAGTA Upstream primer SEQ.ID.NO.9 CAG-R TATACGAAGTTATATCGATAATGCGATACCTCGCAA Downstream primer SEQ.ID.NO.10 Loxp-F GCGAGGTATCGCATTATCGATATAACTTCGTATAGCAT Upstream primer SEQ.ID.NO.11 Loxp-R GTGGATCCGGAACCCTTAATATAACTTCGTATAATGTATG Downstream primer SEQ.ID.NO.12 OsTIR1-F ACGAAGTTATATTAAGGGTTCCGGATCCACTACACG Upstream primer SEQ.ID.NO.13 BG P CCATCTTCTAGATCTCCATAAGAGAAGAGGGACAGCTATGA Downstream primer SEQ.ID.NO.14 3'arm-F TATGGAGATCTAGAAGATGGGCGGGAGTCTTCTGGGC Upstream primer SEQ.ID.NO.15 3'arm-R CCTGGTACCAGAATGCGGCCGCCCCAACCAACAGCAGAG Downstream primer SEQ.ID.NO.16
[0067] 5. Acc65I (NEB, R0599) and AscI (NEB, R0558) endonucleases were used to digest the existing plasmid (customized from Saiye Bio, internal catalog number Cat: VB139; specifically, it was modified from commercial plasmid addgene #50005 to provide a vector backbone). The digestion system is shown in Table 4. The digestion product was subjected to gel electrophoresis and the target band was cut out. The linearized plasmid (4201 bp, i.e., the vector backbone) was recovered and purified using a DNA gel recovery kit (OMEGA, D2000).
[0068] Table 4. Enzyme digestion system
[0069] Components Dosage Plasmid DNA 1.0 μg <![CDATA[10×rCutSmart TM Buffer]]> 5.0μL AscI 1μL NotI 0.5μL <![CDATA[ddH2O]]> To 50.0μL
[0070] 6. Use a seamless cloning kit (NEB, E2621) to connect the PCR amplified fragment with the linearized plasmid according to the reaction system shown in Table 5. The reaction uses a PCR instrument and is incubated at 50° C. for 60 min; then placed on ice for transformation.
[0071] Table 5. In-Fusion System
[0072]
[0073] 7. Add 5 μL of the reaction product obtained using the seamless cloning kit to the DH5-alpha competent cells, mix gently and let stand on ice for 30 min; heat shock at 42°C for 30 s and let stand on ice for 3 min; add 500 μL (room temperature) LB medium to the test tube and put it in a 37°C shaker (220 rpm) for recovery; then take 200 μL of the bacterial solution to apply to the LB plate containing ampicillin, and incubate it upside down at 37°C incubator overnight; pick single clone colonies for bacterial solution PCR identification, and send the successfully connected bacterial solution for sequencing.
[0074] 8. According to the sequencing results, the colonies with successful connection and no mutation were selected for shaking, and the bacterial liquid was collected and the plasmid was extracted using the endotoxin-free plasmid extraction kit (CW2104) to obtain the Donor vector (see Figure 2 ).
[0075] 9. Microinject Cas9 protein (NEB, M0646), gRNA and Donor vector (add 1.6 μL of 100 pmol / μL gRNA to 5.2 μL RNase-free water, add 0.2 μL Cas9 protein and mix well, incubate in a metal bath at 25°C for 10 min to obtain tube 1 solution; tube 2 solution: 13 μL of Donor vector with a final concentration of 15 ng / μL; mix tube 1 solution and tube 2 solution to obtain 20 μL of complex for microinjection) into the fertilized eggs of C57BL / 6J mice, take the fertilized eggs that survive the injection and transplant them into pseudo-pregnant mothers, and give birth to mice in about 20 days, namely F0 generation mice, and identify the genotype of F0 generation mice by PCR method.
[0076] 10. Positive F0 mice were mated with C57BL / 6J mice (wild-type, WT) to obtain F1 mice, and their genotypes were identified by PCR. If positive mice (F1 heterozygotes) were born, it indicated that the knock-in sequence had been integrated into the germ cells.
[0077] 11. The F1 generation heterozygous mice were self-pollinated, and the resulting F2 generation mice were genotyped to obtain Ostir1 homozygous knock-in mice (referred to as knock-in mice).
[0078] 12. The F2 mice were mated with muscle-specific Pax7-Cre mice (provided by Saiye Biotechnology) and the F3 generation was identified as Ostir1 heterozygous and Cre-positive offspring, which were Ostir1 muscle-specific expression mice (denoted as OsTIR1 f / + Pax7 cre / + OsTIR1 flow / + Pax7 cre / + ).
[0079] (II) Mouse genotype PCR identification results
[0080] 1. PCR identification results of F0 generation mouse genotype
[0081] DNA was extracted from the mouse tail tip and its genotype was identified by PCR amplification. Figure 3 According to the PCR identification strategy, the 5'HA homologous recombination positive genome should amplify a 2.6kb fragment, and the negative genome should have no band; the 3'HA homologous recombination positive genome should amplify a 2.6kb fragment, and the negative genome should have no band. Figure 4 As shown,
[0082] Lanes 1, 2, and 3 are F0 mice with positive double-arm homologous recombination. The specific primers used for PCR identification are shown in Table 6:
[0083] Table 6. PCR amplification primers
[0084] Primer name Sequence (5'-3') Primer Type Sequence Listing F1 GCATCTGACTTCTGGCTAATAAAG Upstream primer SEQ.ID.NO.17 R1 ATGGGAAGTTAGTAGCAAACAAGAG Downstream primer SEQ.ID.NO.18 F2 TACGCCACAGGGAGTCCAAGAATG Upstream primer SEQ.ID.NO.19 R2 AGATGTACTGCCAAGTAGGAAAGTC Downstream primer SEQ.ID.NO.20
[0085] 2. Sequencing results of knock-in sequences of F0 mice
[0086] Use primers F3 / R3 for PCR amplification and send the product for sequencing. The sequencing results are as follows Figure 5 The results showed that the knock-in site of the positive F0 generation mice was correct and there was no mutation in the knock-in sequence. Among them, the specific primers used for PCR amplification
[0087] As shown in Table 7:
[0088] Table 7. PCR amplification primers
[0089] Primer name Sequence (5'-3') Primer Type Sequence Listing F3 CACTTGCTCTCCCAAAGTCGCTC Upstream primer SEQ.ID.NO.21 R3 ATACTCCGAGGCGGATCACAA Downstream primer SEQ.ID.NO.22
[0090] 3. PCR identification results of F1 and F2 generation mice genotypes
[0091] DNA was extracted from the mouse tail tip and its genotype was identified by PCR amplification. Figure 3 The PCR identification strategy in the experiment was to use primers F3, F4 and R3 for PCR, and the extension time of the PCR program was set according to the length of 2.5kb. For the wild type, the PCR reaction can obtain a single 485bp band; for the heterozygote, the PCR reaction can obtain 2491bp and 485bp bands; for the homozygote, the PCR reaction can obtain a single 2491bp band.
[0092] The results of genotyping of F1 mice are as follows: Figure 6 As shown, three heterozygous mice and one wild-type (WT) mouse were identified. The genotype identification results of the F2 generation mice are shown in Figure 7As shown, 2 heterozygous mice, 2 wild-type mice and 1 homozygous mouse were identified. Among them, the specific primers used for PCR identification are shown in Table 8:
[0093] Table 8. PCR amplification primers
[0094] Primer name Sequence (5'-3') Primer Type Sequence Listing F3 CACTTGCTCTCCCAAAGTCGCTC Upstream primer SEQ.ID.NO.21 R3 ATACTCCGAGGCGGATCACAA Downstream primer SEQ.ID.NO.22 F4 GGTCTGCAAAGTGTGGTACGA Upstream primer SEQ.ID.NO.23
[0095] 3. Evaluation of transgenic mouse models expressing the plant gene Ostir1
[0096] 1. PCR identification results of F3 generation mouse genotype
[0097] F2 mice were crossed with muscle-specific Pax7-Cre mice, and muscle tissues of F3 mice were collected to extract DNA. Figure 8 PCR identification was performed using the PCR identification strategy in . If there is Cre activity (i.e. Cre works), 3270 bp and 204 bp bands will appear in the PCR reaction; if there is no Cre activity (i.e. Cre does not work), only the 3270 bp band will appear in the PCR reaction.
[0098] The identification results are as follows Fig. 9 As shown, a 204 bp band appeared in the muscle tissue of two mice, both of which were Ostir1 heterozygous and Cre positive mice. Among them, the specific primers used for PCR identification are shown in Table 9:
[0099] Table 9. PCR amplification primers
[0100] Primer name Sequence (5'-3') Primer Type Sequence Listing F5 GGCAACGTGCTGGTTATTGTG Upstream primer SEQ.ID.NO.24 R5 AGACCAGGCTCACTGTGTTTCTAT Downstream primer SEQ.ID.NO.25
[0101] 2. OsTIR1 protein expression identification results
[0102] The expression of OsTIR1 protein in the muscle tissue of F3 mice was detected by Western blot. Fig.10 As shown, the exogenous OsTIR1 protein can be normally expressed in the muscle tissue of Ostir1 heterozygous and Cre-positive mice in the F3 generation.
[0103] The above results show that the present invention successfully constructed a transgenic mouse model expressing the plant gene Ostir1, providing a reference for realizing the expression of plant genes in animals. At the same time, the transgenic mouse model can provide a parent that efficiently expresses the OsTIR1 protein for constructing a protein rapid degradation system model mouse, so that the protein rapid degradation system model mouse can be used to realize the rapid, complete, and reversible degradation of the protein of interest induced by plant growth hormone, providing a new idea and approach to solve the problem that the traditional gene knockout animal model cannot explore the direct regulatory mechanism of the protein of interest.
Claims
1. A method for constructing a transgenic mouse model expressing the plant gene OsTir1, characterized in that: The following steps are involved: 1) knocking in a plant gene OsTir1 expression cassette containing a Loxp-Stop-Loxp sequence into a mouse genome as a target sequence to obtain a knock-in mouse; wherein the plant gene OsTir1 expression cassette comprises a Kozak sequence, an OsTir1 coding sequence and an rBG pA sequence; 2) The knock-in mice were used to remove the Loxp-Stop-Loxp sequence in the genome through homologous recombination to obtain mice with tissue-specific expression of the plant gene Ostir1.
2. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 1, characterized in that: In step 1, the target sequence is knocked into the first intron of the Rosa26 gene on mouse chromosome 6 using CRISPR / Cas9 technology and homologous recombination repair.
3. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 2, characterized in that: The homologous recombination repair is performed on the double-stranded DNA break of the Rosa26 gene caused by the Cas9 protein, and the knock-in site is located at the target site in the first intron of the Rosa26 gene. The sequence of the target site is as follows: 5'—CTCCAGTCTTTCTAGAAGATGGG—3'.
4. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 2, characterized in that: The donor vector used in the homologous recombination repair comprises a 5' homology arm, a promoter for expressing the plant gene OsTir1, a Loxp-Stop-Loxp sequence with the transcription termination sequence 6*SV40 pA as the core, an expression sequence with the Kozak sequence and the plant gene OsTir1 CDS sequence and the rBG pA sequence as the core, and a 3' homology arm, or the donor vector used in the homologous recombination repair comprises a 5' homology arm, a promoter for expressing the plant gene OsTir1, a Loxp-Stop-Loxp sequence with the transcription termination sequence 6*SV40 pA as the core, an expression sequence with the Kozak sequence and the mutated plant gene OsTir1 CDS sequence and the rBG pA sequence as the core, and a 3' homology arm. The pA sequence is an expression sequence and a 3' homology arm composed of the core; wherein the 5' homology arm is a sequence fragment homologous to a 2.1-2.2 kb DNA sequence upstream of the knock-in site in the first intron of the Rosa26 gene, and the 3' homology arm is a sequence fragment homologous to a 2.1-2.2 kb DNA sequence downstream of the knock-in site in the first intron of the Rosa26 gene.
5. A method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 1 or 4, characterized in that: The Loxp-Stop-Loxp sequence specifically includes a termination transcription box located between two loxPs, and the termination transcription box includes a PGK promoter and a 6*SV40 pA sequence.
6. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 5, characterized in that: The termination transcription cassette also includes a resistance gene sequence.
7. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 6, characterized in that: The termination transcription box includes a PGK promoter, a neomycin resistance gene sequence and a 6*SV40 pA sequence.
8. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 4, characterized in that: The step 1 specifically comprises the following steps: 1.1) constructing a donor vector containing the 5' homology arm, CAG promoter, Loxp-Stop-Loxp sequence, the expression sequence and the 3' homology arm; 1.2) Introducing gRNA, Cas9 protein and the constructed donor vector into the fertilized eggs of wild-type mice, and then transplanting the fertilized eggs into pseudo-pregnant female mice, which give birth to F0 generation mice; 1.3) F0 mice are mated with wild-type mice to obtain F1 mice, heterozygous transgenic mice that retain the target sequence in the F1 mice are self-fertilized, and then homozygous transgenic mice that retain the target sequence in the offspring mice are identified.
9. The method for constructing a transgenic mouse model expressing the plant gene OsTir1 according to claim 1, characterized in that: The step 2 specifically includes the following steps: mating the knock-in mice with tissue-specific Cre tool mice to obtain Cre-positive heterozygous transgenic mice.
10. The method for constructing a transgenic mouse model expressing the plant gene Ostir1 according to claim 9, characterized in that: The Cre enzyme of the Cre tool mouse is specifically expressed in muscle tissue.
Citation Information
Cited By
Method for constructing transgenic mouse model of lung tissue specific expression SARS-Cov2 structural protein
CN119709862A
A method of constructing a transgenic mouse model expressing SARS-Cov2 structural proteins specifically in lung tissue
CN119709862B
